山奈酚葡萄糖苷通过靶向Nrf2/NF-κB/NLRP3/GSDMD对脂多糖引起的急性肺损伤的保护作用:实验与计算研究的整合

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Wesam H. Abdulaal , Ulfat M. Omar , Mustafa Zeyadi , Dina S. El-Agamy , Nabil A. Alhakamy , Naif A. R. Almalki , Hani Z. Asfour , Mohammed W. Al-Rabia , Abdulrahim A. Alzain , Gamal A. Mohamed , Sabrin R.M. Ibrahim
{"title":"山奈酚葡萄糖苷通过靶向Nrf2/NF-κB/NLRP3/GSDMD对脂多糖引起的急性肺损伤的保护作用:实验与计算研究的整合","authors":"Wesam H. Abdulaal ,&nbsp;Ulfat M. Omar ,&nbsp;Mustafa Zeyadi ,&nbsp;Dina S. El-Agamy ,&nbsp;Nabil A. Alhakamy ,&nbsp;Naif A. R. Almalki ,&nbsp;Hani Z. Asfour ,&nbsp;Mohammed W. Al-Rabia ,&nbsp;Abdulrahim A. Alzain ,&nbsp;Gamal A. Mohamed ,&nbsp;Sabrin R.M. Ibrahim","doi":"10.1016/j.jsps.2024.102073","DOIUrl":null,"url":null,"abstract":"<div><p>The current study explored the protective potential of kaempferol 3-sophoroside-7-glucoside (KSG) against acute lung injury (ALI). Pre-treatment with KSG effectively secured mice from ALI and showed similar efficaciousness to dexamethasone. KSG markedly increased the survival rate and alleviated lung pathological lesions induced by lipopolysaccharide (LPS). Furthermore, KSG attenuated differential and total cell counts in BALF (bronchoalveolar lavage fluid) and MPO (myeloperoxidase) activity. KSG counteracted the NF-κB (nuclear factor-κB) activation and significantly ameliorated the downstream inflammatory cytokine, TNF-α (tumor necrosis factor-α). Simultaneously, KSG suppressed the over-expression of NLRP3 (NOD-like receptor protein 3<strong>)</strong>, caspase-1, and pro-inflammatory cytokine interleukin IL-1β (interleukine-1β) and prohibited the elevation of the pyroptotic parameter GSDMD-N (N-terminal domain of gasdermin D) induced by LPS challenge. In addition, KSG significantly enhanced Nrf2 (nuclear-factor erythroid-2-related factor) and HO-1 (heme-oxygenase-1) expression. Meanwhile, KSG mitigated lipid peroxidative markers (malondialdehyde, protein carbonyl and 4-hydroxynonenal) and boosted endogenous antioxidants (superoxide dismutase/reduced glutathione/catalase) in lung tissue. <em>In silico</em> analyses revealed that KSG disrupts Keap1-Nrf2 protein–protein interactions by binding to the KEAP1 domain, consequently activating Nrf2. Specifically, molecular docking demonstrated superior binding affinity of KSG to KEAP1 compared to the reference inhibitor, with docking scores of −9.576 and −6.633 Kcal/mol, respectively. Additionally, the MM-GBSA binding free energy of KSG (−67.25 Kcal/mol) surpassed that of the reference inhibitor (−56.36 Kcal/mol). Furthermore, MD simulation analysis revealed that the KSG-KEAP1 complex exhibits substantial and stable binding interactions with various amino acids over a duration of 100 ns. These findings showed the protective anti-inflammatory and anti-oxidative modulatory efficiencies of KSG that effectively counteracted LPS-induced ALI and encouraged future research and clinical applications of KSG as a protective strategy for ALI.</p></div>","PeriodicalId":49257,"journal":{"name":"Saudi Pharmaceutical Journal","volume":"32 6","pages":"Article 102073"},"PeriodicalIF":3.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1319016424001233/pdfft?md5=2838ff40427d3a493238a9e6660eafb3&pid=1-s2.0-S1319016424001233-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Protective effect of kaempferol glucoside against lipopolysaccharide-caused acute lung injury via targeting Nrf2/NF-κB/NLRP3/GSDMD: Integrating experimental and computational studies\",\"authors\":\"Wesam H. Abdulaal ,&nbsp;Ulfat M. Omar ,&nbsp;Mustafa Zeyadi ,&nbsp;Dina S. El-Agamy ,&nbsp;Nabil A. Alhakamy ,&nbsp;Naif A. R. Almalki ,&nbsp;Hani Z. Asfour ,&nbsp;Mohammed W. Al-Rabia ,&nbsp;Abdulrahim A. Alzain ,&nbsp;Gamal A. Mohamed ,&nbsp;Sabrin R.M. Ibrahim\",\"doi\":\"10.1016/j.jsps.2024.102073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The current study explored the protective potential of kaempferol 3-sophoroside-7-glucoside (KSG) against acute lung injury (ALI). Pre-treatment with KSG effectively secured mice from ALI and showed similar efficaciousness to dexamethasone. KSG markedly increased the survival rate and alleviated lung pathological lesions induced by lipopolysaccharide (LPS). Furthermore, KSG attenuated differential and total cell counts in BALF (bronchoalveolar lavage fluid) and MPO (myeloperoxidase) activity. KSG counteracted the NF-κB (nuclear factor-κB) activation and significantly ameliorated the downstream inflammatory cytokine, TNF-α (tumor necrosis factor-α). Simultaneously, KSG suppressed the over-expression of NLRP3 (NOD-like receptor protein 3<strong>)</strong>, caspase-1, and pro-inflammatory cytokine interleukin IL-1β (interleukine-1β) and prohibited the elevation of the pyroptotic parameter GSDMD-N (N-terminal domain of gasdermin D) induced by LPS challenge. In addition, KSG significantly enhanced Nrf2 (nuclear-factor erythroid-2-related factor) and HO-1 (heme-oxygenase-1) expression. Meanwhile, KSG mitigated lipid peroxidative markers (malondialdehyde, protein carbonyl and 4-hydroxynonenal) and boosted endogenous antioxidants (superoxide dismutase/reduced glutathione/catalase) in lung tissue. <em>In silico</em> analyses revealed that KSG disrupts Keap1-Nrf2 protein–protein interactions by binding to the KEAP1 domain, consequently activating Nrf2. Specifically, molecular docking demonstrated superior binding affinity of KSG to KEAP1 compared to the reference inhibitor, with docking scores of −9.576 and −6.633 Kcal/mol, respectively. Additionally, the MM-GBSA binding free energy of KSG (−67.25 Kcal/mol) surpassed that of the reference inhibitor (−56.36 Kcal/mol). Furthermore, MD simulation analysis revealed that the KSG-KEAP1 complex exhibits substantial and stable binding interactions with various amino acids over a duration of 100 ns. These findings showed the protective anti-inflammatory and anti-oxidative modulatory efficiencies of KSG that effectively counteracted LPS-induced ALI and encouraged future research and clinical applications of KSG as a protective strategy for ALI.</p></div>\",\"PeriodicalId\":49257,\"journal\":{\"name\":\"Saudi Pharmaceutical Journal\",\"volume\":\"32 6\",\"pages\":\"Article 102073\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1319016424001233/pdfft?md5=2838ff40427d3a493238a9e6660eafb3&pid=1-s2.0-S1319016424001233-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Pharmaceutical Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1319016424001233\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Pharmaceutical Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1319016424001233","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

本研究探讨了山奈酚 3-槐糖苷-7-葡萄糖苷(KSG)对急性肺损伤(ALI)的保护潜力。预处理 KSG 能有效保护小鼠免受 ALI 的伤害,其疗效与地塞米松相似。KSG 显著提高了小鼠的存活率,并减轻了脂多糖(LPS)诱导的肺部病变。此外,KSG 还能减少支气管肺泡灌洗液(BALF)中的不同细胞数和总细胞数以及 MPO(髓过氧化物酶)活性。KSG 抵消了 NF-κB(核因子-κB)的激活,并显著改善了下游炎症细胞因子 TNF-α(肿瘤坏死因子-α)。与此同时,KSG 还能抑制 NLRP3(NOD 样受体蛋白 3)、caspase-1 和促炎细胞因子白细胞介素 IL-1β(白细胞介素-1β)的过度表达,并抑制 LPS 挑战诱导的热解参数 GSDMD-N(N-端域 gasdermin D)的升高。此外,KSG 还能明显提高 Nrf2(核因子红细胞-2 相关因子)和 HO-1(血红素加氧酶-1)的表达。同时,KSG 还能减轻肺组织中的脂质过氧化标记物(丙二醛、蛋白质羰基和 4-羟基壬烯醛),并增强内源性抗氧化剂(超氧化物歧化酶/还原型谷胱甘肽/催化酶)。硅学分析表明,KSG通过与KEAP1结构域结合,破坏了Keap1-Nrf2蛋白质之间的相互作用,从而激活了Nrf2。具体来说,分子对接表明,与参考抑制剂相比,KSG与KEAP1的结合亲和力更强,对接得分分别为-9.576和-6.633 Kcal/mol。此外,KSG 的 MM-GBSA 结合自由能(-67.25 Kcal/mol)超过了参考抑制剂(-56.36 Kcal/mol)。此外,MD 模拟分析表明,KSG-KEAP1 复合物在 100 ns 的持续时间内与各种氨基酸表现出大量稳定的结合相互作用。这些研究结果表明,KSG 具有保护性抗炎和抗氧化调节功效,可有效对抗 LPS 诱导的 ALI,并鼓励未来将 KSG 作为 ALI 的保护性策略进行研究和临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Protective effect of kaempferol glucoside against lipopolysaccharide-caused acute lung injury via targeting Nrf2/NF-κB/NLRP3/GSDMD: Integrating experimental and computational studies

The current study explored the protective potential of kaempferol 3-sophoroside-7-glucoside (KSG) against acute lung injury (ALI). Pre-treatment with KSG effectively secured mice from ALI and showed similar efficaciousness to dexamethasone. KSG markedly increased the survival rate and alleviated lung pathological lesions induced by lipopolysaccharide (LPS). Furthermore, KSG attenuated differential and total cell counts in BALF (bronchoalveolar lavage fluid) and MPO (myeloperoxidase) activity. KSG counteracted the NF-κB (nuclear factor-κB) activation and significantly ameliorated the downstream inflammatory cytokine, TNF-α (tumor necrosis factor-α). Simultaneously, KSG suppressed the over-expression of NLRP3 (NOD-like receptor protein 3), caspase-1, and pro-inflammatory cytokine interleukin IL-1β (interleukine-1β) and prohibited the elevation of the pyroptotic parameter GSDMD-N (N-terminal domain of gasdermin D) induced by LPS challenge. In addition, KSG significantly enhanced Nrf2 (nuclear-factor erythroid-2-related factor) and HO-1 (heme-oxygenase-1) expression. Meanwhile, KSG mitigated lipid peroxidative markers (malondialdehyde, protein carbonyl and 4-hydroxynonenal) and boosted endogenous antioxidants (superoxide dismutase/reduced glutathione/catalase) in lung tissue. In silico analyses revealed that KSG disrupts Keap1-Nrf2 protein–protein interactions by binding to the KEAP1 domain, consequently activating Nrf2. Specifically, molecular docking demonstrated superior binding affinity of KSG to KEAP1 compared to the reference inhibitor, with docking scores of −9.576 and −6.633 Kcal/mol, respectively. Additionally, the MM-GBSA binding free energy of KSG (−67.25 Kcal/mol) surpassed that of the reference inhibitor (−56.36 Kcal/mol). Furthermore, MD simulation analysis revealed that the KSG-KEAP1 complex exhibits substantial and stable binding interactions with various amino acids over a duration of 100 ns. These findings showed the protective anti-inflammatory and anti-oxidative modulatory efficiencies of KSG that effectively counteracted LPS-induced ALI and encouraged future research and clinical applications of KSG as a protective strategy for ALI.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Saudi Pharmaceutical Journal
Saudi Pharmaceutical Journal PHARMACOLOGY & PHARMACY-
CiteScore
6.10
自引率
2.40%
发文量
194
审稿时长
67 days
期刊介绍: The Saudi Pharmaceutical Journal (SPJ) is the official journal of the Saudi Pharmaceutical Society (SPS) publishing high quality clinically oriented submissions which encompass the various disciplines of pharmaceutical sciences and related subjects. SPJ publishes 8 issues per year by the Saudi Pharmaceutical Society, with the cooperation of the College of Pharmacy, King Saud University.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信